Premium
Acetylcholinesterase inhibitors reduce brain and blood interleukin‐1β production
Author(s) -
Pollak Yehuda,
Gilboa Adi,
BenMenachem Ofra,
BenHur Tamir,
Soreq Hermona,
Yirmiya Raz
Publication year - 2005
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20454
Subject(s) - acetylcholinesterase , tacrine , rivastigmine , cholinergic , pharmacology , neostigmine , medicine , acetylcholinesterase inhibitor , chemistry , donepezil , enzyme , dementia , disease , biochemistry
Overproduction of interleukin‐1 within the brain is associated with Alzheimer's disease and other neurological conditions. We report that peripheral administration of the acetylcholinesterase inhibitors tacrine, rivastigmine, neostigmine, or EN101 (an antisense oligonucleotide directed at acetylcholinesterase messenger RNA) to mice significantly attenuated the production of interleukin‐1β in the hippocampus and blood, concomitantly with the reduction in acetylcholinesterase activity. These findings demonstrate that cholinergic enhancement produces central and peripheral antiinflammatory effects and suggest a novel therapeutic mechanism for acetylcholinesterase inhibitors. Ann Neurol 2005